Immune globulin intravenous replacement after plasma exchange

Area of Science:

• Immunology
• Neurology
• Pharmacology

Background:

• Autoimmune diseases can lead to IgG deficiency.
• Plasma exchange removes essential immunoglobulins.
• Replacement therapy is crucial for managing autoimmune conditions.

Purpose of the Study:

• To evaluate the safety and efficacy of high-dose immune globulin intravenous (IGIV) for IgG replacement.
• To compare IGIV with immune serum globulin (ISG) in restoring IgG levels post-plasma exchange.
• To assess adverse events associated with IGIV infusions in patients with autoimmune diseases.

Main Methods:

• Administered high-dose IGIV (275 mg/kg) to 64 patients with autoimmune diseases undergoing plasma exchange.
• Monitored for side effects during and after IGIV infusions.
• Measured serum IgG levels to assess replacement efficacy.
• Compared IGIV efficacy to intramuscular ISG injection.

Main Results:

• IGIV infusions rapidly restored serum IgG levels to the normal range.
• 15% of IGIV infusions had mild, transient side effects, manageable by slowing the infusion rate.
• 2% of infusions were terminated due to severe side effects; chills were most common.
• IGIV was more effective than ISG in restoring IgG levels post-plasma exchange.
• High-dose IGIV was well-tolerated over multiple infusions.
• No protection against Herpes zoster was observed.
• No short-term impact on anti-acetylcholine receptor antibody titers in myasthenia gravis patients.

Conclusions:

• High-dose IGIV is a safe and effective method for replacing IgG removed during plasma exchange.
• IGIV offers a superior alternative to ISG for IgG restoration post-plasma exchange.
• While generally safe, potential side effects require monitoring and management.